Inventor · disambiguated record
Martin Bossart
Also filed as: BOSSART MARTIN
20 granted patents·4 pending applications·52 citations·filing 2006–2021
92Inventor score
Files withSANOFI SA17SANOFI AVENTIS DEUTSCHLAND3ANTAROS MEDICAL AB2AVENTIS PHARMA SA1SCHWINK LOTHAR1
Top patents by PatentIndex Score
24 records- 0187US9365632B2Exendin-4 derivatives as dual GLP1/glucagon agonistsSANOFI SA·Filed 2013·Granted Jun 14, 2016·9 cites·38 claims
- 0284US9758561B2Dual GLP-1/glucagon receptor agonists derived from exendin-4SANOFI SA·Filed 2015·Granted Sep 12, 2017·6 cites·34 claims
- 0383US7727989B24-benzimidazol-2-yl-pyridazine-3-one-derivatives, production and use thereof in medicamentsSANOFI AVENTIS DEUTSCHLAND·Filed 2006·Granted Jun 1, 2010·7 cites·11 claims
- 0482US8853412B2Pyrrolidinone derivatives as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disordersSCHWINK LOTHAR·Filed 2013·Granted Oct 7, 2014·6 cites·31 claims
- 0581US9775904B2Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonistsSANOFI SA·Filed 2015·Granted Oct 3, 2017·4 cites·27 claims
- 0681US9771406B2Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4SANOFI SA·Filed 2015·Granted Sep 26, 2017·4 cites·31 claims
- 0779US9694053B2Dual GLP-1/glucagon receptor agonistsSANOFI SA·Filed 2014·Granted Jul 4, 2017·4 cites·22 claims
- 0877US10538567B2Compounds as peptidic trigonal GLP1/glucagon/GIP receptor agonistsSANOFI SA·Filed 2017·Granted Jan 21, 2020·2 cites·38 claims
- 0977US10519211B2Compounds as peptidic GLP1/glucagon/GIP receptor agonistsSANOFI SA·Filed 2017·Granted Dec 31, 2019·2 cites·30 claims
- 1076US9982029B2Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonistsSANOFI SA·Filed 2016·Granted May 29, 2018·2 cites·34 claims
- 1174US10792367B2Conjugates comprising an GLP-1/glucagon dual agonist, a linker and hyaluronic acidSANOFI SA·Filed 2017·Granted Oct 6, 2020·1 cites·36 claims
- 1271US7968546B2Pyridazinone kinase inhibitorsSANOFI AVENTIS DEUTSCHLAND·Filed 2009·Granted Jun 28, 2011·1 cites·10 claims
- 1371US7709466B2Pyridazinone derivatives, methods for their production and their use as pharmaceuticalsSANOFI AVENTIS DEUTSCHLAND·Filed 2006·Granted May 4, 2010·1 cites·9 claims
- 1470US7507734B2Pyridazinone derivativesAVENTIS PHARMA SA·Filed 2006·Granted Mar 24, 2009·1 cites·8 claims
- 1567US9221784B2Benzo[1,3]dioxine derivatives and their use as LPAR5 antagonistsSANOFI SA·Filed 2013·Granted Dec 29, 2015·1 cites·10 claims
- 1663US11046743B2Selective glucagon receptor agonists comprising a chelating moiety for imaging purposesANTAROS MEDICAL AB·Filed 2016·Granted Jun 29, 2021·1 cites·20 claims
- 1755US10758592B2Exendin-4 derivatives as dual GLP1/glucagon agonistsSANOFI SA·Filed 2017·Granted Sep 1, 2020·0 cites·23 claims
- 1852US11141489B2Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic acidSANOFI SA·Filed 2019·Granted Oct 12, 2021·0 cites·20 claims
- 1950US2016220643A1Exendin-4 derivatives as dual glp1/glucagon agonistsSANOFI SA·Filed 2016·Application pending·0 cites
- 2050US2023127047A1Selective gip receptor agonists comprising a chelating moiety for imaging and therapy purposesANTAROS MEDICAL AB·Filed 2021·Application pending·0 cites
- 2146US2015166625A1Exendin-4 Peptide AnaloguesSANOFI SA·Filed 2014·Application pending·0 cites
- 2246US2017022260A9Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonistsSANOFI SA·Filed 2014·Application pending·0 cites
- 2341US10806797B2Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugateSANOFI SA·Filed 2016·Granted Oct 20, 2020·0 cites·28 claims
- 2439US11352405B2GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitisSANOFI SA·Filed 2018·Granted Jun 7, 2022·0 cites·17 claims
Join the waitlist — get patent alerts
Get an alert when Martin Bossart files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →